Accéder au contenu
Merck

Ceftriaxone preconditioning confers neuroprotection in neonatal rats through glutamate transporter 1 upregulation.

Reproductive sciences (Thousand Oaks, Calif.) (2011-06-23)
Kazuya Mimura, Takuji Tomimatsu, Kenji Minato, Otgonbaatar Jugder, Yukiko Kinugasa-Taniguchi, Takeshi Kanagawa, Masatoshi Nozaki, Itaru Yanagihara, Tadashi Kimura
RÉSUMÉ

This study investigated the hypothesis that ceftriaxone preconditioning ameliorates brain damage in neonatal animals through glutamate transporter 1 (GLT-1) upregulation. Sprague Dawley rats were pretreated with ceftriaxone, erythromycin, minocycline, or saline for 5 consecutive days starting from postnatal day 2 (P2), and GLT-1/glutamate-aspartate transporter (GLAST) messenger RNA (mRNA) and protein levels were examined in the P7 brains. After ceftriaxone or saline preconditioning, the P7 rats underwent hypoxic-ischemic (H-I) procedure or sham operation. One week after the procedure (P14), hematoxylin-eosin staining, microtubule-associated protein 2 (MAP-2) immunostaining, and transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay were used to examine neuronal damage and possible neurotoxicity. Repeated ceftriaxone injections significantly increased GLT-1 mRNA and protein levels but not GLAST. Following such treatment and H-I procedure, the MAP-2-positive area increased and TUNEL-positive cells decreased. Antenatal ceftriaxone may help to provide neuroprotection in the immature brain and become a new prophylactic strategy to reduce neonatal encephalopathy in clinical perinatal medicine.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ceftriaxone disodium salt hemi(heptahydrate), third-generation cephalosporin antibiotic